Literature DB >> 16328345

Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.

Jia Hu Hao1, Dong Qing Ye, Guo Qing Zhang, Hui Hui Liu, Hong Dai, Fen Huang, Fa Ming Pan, Hong Su, Ma Xia Dong, Hong Chen, Qian Wang, Xue Jun Zhang.   

Abstract

The aims of the present study are to evaluate the difference of the levels of soluble Fas (sFas) antigen between patients with systemic lupus erythematosus (SLE) and healthy controls and to explore whether sFas has a role in either the disease activity or the organ damage in SLE. Serum levels of sFas were measured in 40 Chinese patients with SLE and 15 age-, gender-, and race-matched healthy controls using double antibody ELISA. SLEDAI scores for disease activity were determined. Data of organ and tissue damage was obtained from clinical records. Serum sFas levels were significantly increased in both more active (mean=8043.8 pg/ml, P<0.001) and less active SLE patients (mean=4820.2 pg/ml, P<0.001) comparing to the healthy controls (mean=3253.4 pg/ml). There was also a significant difference in serum sFas levels between the more active SLE patients and less active SLE patients (P=0.04). But, the levels of sFas didn't correlate with SLEDAI. There was a significant difference in the serum sFas levels between patients with and without CNS disease (mean=9582.6, 6634.5 pg/ml; P=0.007). The same was true when patients with and without renal disease (mean=10972.7, 6520.1 pg/ml; P=0.019), as well as serositis (mean=10385.3, 6709.1 pg/ml; P=0.005) were analyzed. sFas is elevated in sera of SLE patients, especially in patients with active SLE. The elevated levels of sFas in the sera of patients with SLE may be closely associated with damage to the kidneys, central nervous system and serosa. Serum sFas may serve as a predictor of some organ and tissue damage in SLE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328345     DOI: 10.1007/s00403-005-0616-2

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

1.  Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus.

Authors:  Maryam Sahebari; Zahra Rezaieyazdi; Mohammadreza J Nakhjavani; Mohammadreza Hatef; Mahmoud Mahmoudi; Saaid Akhlaghi
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

2.  Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena B Kiss; Solange Carrasco; Patrícia Palmeira; Claudia Goldenstein-Schainberg; Magda Carneiro-Sampaio
Journal:  Clin Rheumatol       Date:  2017-04-04       Impact factor: 2.980

3.  Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

Authors:  Nan Xiang; Xiao-Mei Li; Guo-Sheng Wang; Jin-Hui Tao; Xiang-Pei Li
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

4.  Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis.

Authors:  Lian-Hong Li; Wen-Xian Li; Ou Wu; Guo-Qing Zhang; Hai-Feng Pan; Xiang-Pei Li; Jian-Hua Xu; Hong Dai; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2008-11-20       Impact factor: 2.316

5.  Soluble fas and the -670 polymorphism of fas in lupus nephritis.

Authors:  Juan José Bollain-Y-Goytia; Mariela Arellano-Rodríguez; Felipe de Jesús Torres-Del-Muro; Leonel Daza-Benítez; José Francisco Muñoz-Valle; Esperanza Avalos-Díaz; Rafael Herrera-Esparza
Journal:  Int J Nephrol       Date:  2014-11-18

6.  FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome.

Authors:  Zhahirul Islam; Israt Jahan; Rijwan U Ahammad; Mohammad Shahnaij; Shamsun Nahar; Quazi D Mohammad
Journal:  PLoS One       Date:  2018-02-12       Impact factor: 3.240

7.  Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus.

Authors:  Mohammad Reza Hatef; Maryam Sahebari; Zahra Rezaieyazdi; Mohammad Reza Nakhjavani; Mahmoud Mahmoudi
Journal:  ISRN Rheumatol       Date:  2013-03-14

8.  Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.

Authors:  Fabien B Vincent; Rangi Kandane-Rathnayake; Rachel Koelmeyer; James Harris; Alberta Y Hoi; Fabienne Mackay; Eric F Morand
Journal:  Lupus Sci Med       Date:  2020-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.